Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03947281
Other study ID # FL107
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date June 24, 2019
Est. completion date August 8, 2022

Study information

Verified date August 2022
Source USDA, Western Human Nutrition Research Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to compare two types of snacks (almonds or a cereal-based snack), eaten between meals, on measures of appetite, including appetitive hormones, self-reported feelings of hunger and fullness, and food intake at a buffet meal or in the home environment. The investigators hypothesize that the acute responses of appetitive hormones to a meal challenge protocol will differ between almond and cereal-based snacks based on multivariate models of satiety that will be predictive of ad libitum food intake at a dinner meal as part of the meal challenge protocol. Further, the investigators will estimate if, under free-living conditions, self-selected and self-reported food intake will show appropriate energy compensation for the added calories of the snacks, and determine if one type of snack is superior to the other in this regard.


Description:

This study will use a randomized, parallel design that includes an almond snack intervention and a cereal-based snack intervention group. The almond intervention will be roasted, unsalted almonds at a level of 56 grams per day for 4 weeks. The cereal-based intervention will be isocaloric snacks provided in the form of a mixture of dry cereal, pretzels, and bread sticks for 4 weeks. A satiety test protocol will be done at the beginning and the end of the intervention period. Each test day will include measures of satiety responses to two standard meals, two snacks (either almonds or cereal-based snacks), and a dinner buffet. The protocol to evaluate satiety signals include tonic measures that may signal homeostasis to the brain and evaluation of episodic signals that may drive food intake In addition, other modulators of satiety will be tested including evaluation of preferences for palatable foods, self-reports of cravings and satiety using questionnaires, and perceived hunger, fullness, desire to eat.


Recruitment information / eligibility

Status Terminated
Enrollment 10
Est. completion date August 8, 2022
Est. primary completion date August 8, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Pre-menopausal - Body Mass Index 25 - 39.9 kg/m2 Exclusion Criteria: - Women who are post-menopausal or peri-menopausal - BMI < 25 or > 40 kg/m2 - Allergies to tree nuts - Using any hormonal contraception including oral contraceptive, contraceptive patch, contraceptive ring, contraceptive injection (e.g. Depo-Provera), or contraceptive implant (e.g. Nexplanon/Implanon) - Menstrual cycle lengths < 25 days or > 45 days, or have amenorrhea, eumenorrhea, or polymenorrhea. - Pregnant or nursing within the last 6 months, or plan to become pregnant during the trial - Medical diagnoses of chronic diseases including cardiovascular or pulmonary diseases, renal disease, cancer, type 1 or type 2 diabetes mellitus, thyroid disease requiring medication, inflammatory bowel disease, irritable bowel disease, or those with recent major surgeries - current medical diagnosis of polycystic ovarian syndrome (PCOS).

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Almond snack
The almond intervention will be roasted, unsalted almonds provided at 56 g/day for 28 days. Almonds provide approximately 350 kcals/day.
Cereal-based snack
The cereal-based intervention will be a prepared mix of cereal, pretzels, and bread sticks prepared at the WHNRC. It will be provided at the level of 350 kcals per day for 28 days.

Locations

Country Name City State
United States USDA, ARS, Western Human Nutrition Research Center Davis California

Sponsors (2)

Lead Sponsor Collaborator
USDA, Western Human Nutrition Research Center Almond Board of California

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Baseline level and change in cholecystokinin Cholecystokinin (CCK) measured in blood using an antibody based assay Baseline, 60 minutes before lunch meal, and 10, 30, 90, 150, 180, 210, 240, and 270 minutes after a lunch meal
Primary Baseline level and change in peptide-YY Peptide-YY (PYY) measured in blood using an antibody based assay Baseline, 60 minutes before lunch meal, and 10, 30, 90, 150, 180, 210, 240, and 270 minutes after a lunch meal
Primary Baseline level and change in glucose-like peptide 1 Glucose-like peptide 1 (GLP-1) measured in blood using an antibody based assay Baseline, 60 minutes before lunch meal, and 10, 30, 90, 150, 180, 210, 240, and 270 minutes after a lunch meal
Primary Baseline level and change in gastric inhibitory peptide Gastric inhibitory peptide (GIP) measured in blood using an antibody based assay Baseline, 60 minutes before lunch meal, and 10, 30, 90, 150, 180, 210, 240, and 270 minutes after a lunch meal
Primary Baseline level and change in insulin Insulin measured in blood using an antibody based assay Baseline, 60 minutes before lunch meal, and 10, 30, 90, 150, 180, 210, 240, and 270 minutes after a lunch meal
Primary Baseline level and change in glucose Glucose measured by standard chemistry in blood Baseline, 60 minutes before lunch meal, and 10, 30, 90, 150, 180, 210, 240, and 270 minutes after a lunch meal
Primary Baseline level and change in oleoylethanolamide Oleoylethanolamide measured by mass spectrometry in blood Baseline, 60 minutes before lunch meal, and 10, 30, 90, 150, 180, 210, 240, and 270 minutes after a lunch meal
Primary Baseline level and change in ghrelin Ghrelin measured in blood using an antibody based assay Baseline, 60 minutes before lunch meal, and 10, 30, 90, 150, 180, 210, 240, and 270 minutes after a lunch meal
Primary Baseline level and change in leptin Leptin measured in blood using an antibody based assay Baseline, 60 minutes before lunch meal, and 10, 30, 90, 150, 180, 210, 240, and 270 minutes after a lunch meal
Primary Baseline level and change in orexin Orexin measured in blood using an antibody based assay Baseline, 60 minutes before lunch meal, and 10, 30, 90, 150, 180, 210, 240, and 270 minutes after a lunch meal
Primary Baseline level and change in endocannabinoid profiles Endocannabinoid profiles measured by mass spectrometry in blood Baseline, 60 minutes before lunch meal, and 10, 30, and 150 minutes after a lunch meal
Primary Baseline level and change in hunger Self-reported feelings of hunger measured on a visual analog scale. Responses will be a marked on an unsegmented line from 0 or "not at all" to 100 or "extremely." Baseline, every 30 minutes up to 480 minutes, and immediately before and after three meals
Primary Baseline level and change in satiety Self-reported feelings of fullness measured on a visual analog scale. Responses will be a marked on an unsegmented line from 0 or "not at all" to 100 or "extremely." Baseline, every 30 minutes up to 480 minutes, and immediately before and after three meals
Primary Change in food intake at a dinner meal Calories consumed at a dinner meal following the satiety protocol Week 1 and 4
Secondary Body composition reference measurement Body composition (fat mass and fat-free mass in kg) will be measured once during the study using dual energy x-ray absorptiometry (DEXA) Week 1
Secondary Change in body weight measured in kg Weeks 0, 1, 2, 3, and 4
Secondary Change in body fat measured in kg using multi frequency bioimpedance Weeks 0, 1, 2, 3, and 4
Secondary Change in lean body mass measured in kg using multi frequency bioimpedance Weeks 0, 1, 2, 3, and 4
Secondary Change in total body water measured in kg using multi frequency bioimpedance Weeks 0, 1, 2, 3, and 4
Secondary Change in waist circumference measured in cm Week 0 and 4
Secondary Change in hip circumference measured in cm Week 0 and 4
Secondary Change in Food Choice Food choice computer-based tests from Leeds, United Kingdom, will be used to estimate explicit liking and implicit wanting for several different categories of foods. Baseline and following a lunch meal at Weeks 0 and 4
Secondary Change in food craving Food craving estimated from the questionnaire, Food Craving Inventory, on a 5 point likert scale Week 0 and 4
Secondary Change in self-reported satiety Self reported satiety measured using the 5-factor satiety questionnaire. Scale is a generalized labeled magnitude scale of 150 mm Subscales include mental hunger, physical hunger, mental fullness, physical fullness, and satiation. Subscale scores will range from 0 to 150. Week 0 and 4
Secondary Power of food questionnaire Power of food questionnaire measured once on a 5 point likert scale Week 0
Secondary Food addiction questionnaire Yale food addiction questionnaire measured once on a 5-point likert scale Week 0
Secondary Eating behavior Dutch eating behavior questionnaire measured once. Scale is a 5-point likert scale. Sub scales include restrained eating, emotional eating, and external eating. Scores will be reported separately for each subscale. Week 0
Secondary Three factor eating inventory Three factor eating inventory questionnaire measured once. Instrument has three subscales, combining likert scales and true/false questions. Subscales include cognitive restraint (score can range from 0 to 21), disinhibition (score can range from 0 to 16) and hunger (score can range from 0 to 14). Week 0
Secondary Premenstrual Syndrome Premenstrual Syndrome screening questionnaire measured once. Scale is a 4-point likert. Subscales for premenstrual syndrome (PMS) or premenstrual dysphoric disorder (PMDD), reported separately. Week 0
Secondary General health and well-being The SF-36 General Health and Well-being questionnaire measured once Week 0
Secondary Usual physical activity Physical activity estimated from the Stanford Brief Physical Activity questionnaire. Scale is categorical for two subscales: work physical activity and leisure time activity. Week 0
Secondary Change in metabolic rate Resting and post-prandial metabolic rate measured using indirect calorimetry. Baseline and 1 hour before lunch meal, 1 hour after lunch meal, and 1 hour after mid-afternoon snack
Secondary Change in dietary intake Dietary intake estimated from 24-hour recall using a web based automated multi-pass method Ten dietary recalls collected at home during weeks 1-4
Secondary Genetic risk of obesity A polygenic risk score (PRS) indexing genetic predisposition to obesity using known obesity single nucleotide polymorphisms (SNPs). Week 1
Secondary Change in liver fat Liver fat assessed from the Controlled Attenuation Parameter (CAP) computed from the liver stiffness measurement using the Fibroscan® Week 0 and 4
Secondary Change in liver stiffness Liver stiffness assessed from the shear wave speed with pulse echo ultrasound using the Fibroscan® Week 0 and 4
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2